WIXOM, Mich., Oct. 5, 2009 (GLOBE NEWSWIRE) -- Rockwell Medical Technologies, Inc. (Nasdaq:RMTI), a fully-integrated biopharmaceutical company offering innovative products and services targeting end-stage renal disease (ERSD), chronic kidney disease (CKD), and iron deficiency anemia, announced today that it has received gross proceeds of approximately $22.0 million, before deducting placement agents' fees and offering expenses, from the closing of the previously announced registered direct offering. In the offering, an aggregate of 2,840,000 shares of the Company's common stock and warrants to purchase up to 1,079,200 shares of common stock were sold to institutional investors, led by Deerfield Management as the lead investor.
